Filter results by

Guidance and Policy (5883)
Guidance (30)
Quality Indicators (1)
Prescribing and Technical Information (5821)
Safety Alerts (31)
Practice Based Information (42)
Audit and Inspection Reports (42)
Medicines Current Awareness (57)
Implementation Support (1)
Information for the Public (2)

Area of interest

Drugs and Technologies (58)

Source

Action on Smoking and Health - ASH (1)
Age UK (2)
All Wales Medicines Strategy Group - AWMSG (17)
Alzheimer's Society (1)
British Heart Foundation (1)
Care Quality Commission - CQC (3)
Department of Health (2)
Diabetes UK (4)
electronic Medicines Compendium - eMC (183)
GOV UK (2)
Health Foundation (8)
Healthcare Quality Improvement Partnership - HQIP (3)
House of Commons (1)
King's Fund (7)
Local Government Association (2)
Medicines and Healthcare products Regulatory Agency - MHRA (45)
National Audit Office - NAO (2)
National Institute for Health and Care Excellence - NICE (424)
NHS England (33)
NHS Improvement (11)
NHS Providers (1)
NICE Quality and Productivity Case Studies (1)
NIHR Dissemination Centre (15)
Nuffield Trust (4)
Public Health England - PHE (39)
Royal College of Obstetricians and Gynaecologists - RCOG (1)
Royal Pharmaceutical Society (7)
Scottish Intercollegiate Guidelines Network - SIGN (1)
Scottish Medicines Consortium - SMC (26)
Specialist Pharmacy Service (38)
US Food and Drug Administration - FDA (20)

British National Formulary for Children - BNFc (0)
Royal College of Psychiatrists - RCPsych (2)
Brain Tumour Charity (0)
Arthritis Research UK (0)
Canadian Paediatric Society (0)
British HIV Association - BHIVA (0)
European Society of Gastrointestinal Endoscopy (0)
European Medicines Agency - EMA (56)

Date

From

To

View filters

Share
Linked In
Twitter
Facebook
Email
More...

Results for all evidence | Drugs and Technologies | European Medicines Agency - EMA | Medicines Current Awareness 1 - 10 of 58 sorted by relevance / date

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Warning, download options selected.

The operation that you have selected will move away from the current results page, your download options will not persist.

Please click "Confirm" if you are happy to lose these search results.

The Prescribing Observatory for Mental Health Topic 10 audit report

Remove: Royal College of Psychiatrists - RCPsych source - 01 January 2016 - Publisher: Royal College of Psychiatrists

An audit-based quality improvement programme to help mental health services improve prescribing of antipsychotics for children and adolescents. It is open to all secondary mental health services in...

Read Summary

- More: Implementation Support

- Remove: Quality Indicators filter
Pharmacovigilance Risk Assessment Committee (PRAC) recommend restrictions in use of cyproterone due to meningioma (non-cancerous brain tumour) risk

Remove: European Medicines Agency - EMA source - 14 February 2020 - Publisher: European Medicines Agency

PRAC has recommended that medicines with daily doses of = 10 mg of cyproterone should only be used for androgen-dependent conditions e.g. hirsutism, alopecia, acne and seborrhoea; once other...

Remove: Medicines Current Awareness filter

- More: Safety Alerts
Delivering the NHS Long-Term Plan's ambition of ageing well: Old age psychiatry as a vital resource [PDF]

Remove: Royal College of Psychiatrists - RCPsych source - 21 October 2019 - Publisher: Royal College of Psychiatrists

Report aims to support decision-makers responsible for implementing NHS Long-Term Plan as it affects older people in providing a clear case for need for high-quality, well-led mental health support, ...

Read Summary

- Remove: Medicines Current Awareness filter
Committee for Medicinal Products for Human Use (CHMP) recommends approval of osilodrostat (Isturisa) for treatment of Cushing's syndrome [PDF]

Remove: European Medicines Agency - EMA source - 15 November 2019 - Publisher: European Medicines Agency

Osilodrostat inhibits 11-beta-hydroxylase (CYP11B1), an enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. The expected benefits include the ability to control or...

Read Summary

- Remove: Medicines Current Awareness filter
Committee for Medicinal Products for Human Use (CHMP) recommends approval of siponimod (Mayzent) for treatment of multiple sclerosis [PDF]

Remove: European Medicines Agency - EMA source - 15 November 2019 - Publisher: European Medicines Agency

Siponimod is a selective immunosuppressant acting as a sphingosine 1-phosphate receptor modulator on lymphocytes, thus reducing the recirculation of T-cells into the central nervous system and...

Read Summary

- Remove: Medicines Current Awareness filter
Committee for Medicinal Products for Human Use (CHMP) recommends approval of polatuzumab vedotin (Polivy) for treatment of diffuse large B-cell lymphoma [PDF]

Remove: European Medicines Agency - EMA source - 15 November 2019 - Publisher: European Medicines Agency

Polatuzumab vedotin is a CD79b targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent to B cells. Expected benefits, in combination with bendamustine and rituximab...

Read Summary

- Remove: Medicines Current Awareness filter
Committee for Medicinal Products for Human Use (CHMP) recommends approval of solriamfetol (Sunosi) for treatment of narcolepsy and obstructive sleep apnoea [PDF]

Remove: European Medicines Agency - EMA source - 15 November 2019 - Publisher: European Medicines Agency

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor. The expected benefits are its ability to improve patients’ wakefulness and to reduce their daytime sleepiness.

Read Summary

- Remove: Medicines Current Awareness filter
Committee for Medicinal Products for Human Use (CHMP) recommends approval of fostamatinib (Tavlesse) for treatment of primary immune thrombocytopenia [PDF]

Remove: European Medicines Agency - EMA source - 15 November 2019 - Publisher: European Medicines Agency

Fostamatinib blocks spleen tyrosine kinase, which plays a key role in antibody-mediated cellular responses, thereby reducing antibody-mediated destruction of platelets. Expected benefits include an...

Read Summary

- Remove: Medicines Current Awareness filter
Committee for Medicinal Products for Human Use (CHMP) recommends approval of clopidogrel / acetylsalicylic acid (Mylan) for secondary prevention of atherothrombotic events [PDF]

Remove: European Medicines Agency - EMA source - 15 November 2019 - Publisher: European Medicines Agency

Clopidogrel/Acetylsalicylic acid Mylan is a bioequivalent generic of DuoPlavin, which has been authorised in the EU since 15 March 2010. It will be available as film-coated tablets (75 mg clopidogrel...

SPS comment

- Remove: Medicines Current Awareness filter
Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for license extension of trastuzumab emtansine (Kadcyla) [PDF]

Remove: European Medicines Agency - EMA source - 15 November 2019 - Publisher: European Medicines Agency

The proposed license extension is for adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after...

Read Summary

- Remove: Medicines Current Awareness filter

1
2
3
4
5
6
Next